AI-Driven Personalization of End-of-Life Care for the Elderly

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorBaqiyatallah Medical Sciences University

About this trial

This study aims to evaluate the effectiveness of an artificial intelligence (AI)-based software in personalizing high-quality end-of-life care for elderly patients. As the elderly population grows, providing tailored and quality care during the final stages of life becomes increasingly important. This AI software continuously monitors vital signs and behaviors through wearable sensors, offers smart medication reminders, alerts the care team to potential risks, and provides personalized care plans along with psychological and social support.

The study is designed as a randomized controlled trial comparing two groups: one receiving standard end-of-life care and the other using the AI software. Key outcomes include improving quality of life, reducing adverse events like falls and emergency hospitalizations, increasing patient and family satisfaction, improving medication management, and reducing caregiver burden. Data will be collected over six months to assess these effects. The results will help determine whether AI technology can enhance end-of-life care for seniors and support families and healthcare providers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • AI-based Software for Personalized End-of-Life Care

    Behavioral

    This intervention involves the use of an AI-powered software system designed to personalize end-of-life care for elderly patients. The software continuously monitors vital signs and behavior through wearable sensors, sends smart medication reminders, issues preventive alerts to care providers, delivers customized care plans, and provides psychological and social support through communication features.

Treatment groups

140 Participants
are divided into 2 treatment groups
Group A: AI-based Personalized End-of-Life CareExperimental treatment 1 intervention
Group B: Standard End-of-Life CareActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Quality of Life Score

Assessed using a validated instrument such as the Quality of Life at the End of Life (QUAL-E) scale to measure overall well-being, comfort, and satisfaction with care during end-of-life.

Time frame
Up to 3 months after intervention start

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: